Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Ralf Huss

Premium

Definiens has tapped Ralf Huss to serve as its chief medical officer. In this position, Huss will play a key role in expanding the company's reach in the image and data analysis market, the company said.

Huss is a surgical and anatomical pathologist with more than 20 years of training and experience in histopathology and cancer research. Prior to joining Definiens, he served as the global head of the histopathology and tissue biomarker arm at Roche Diagnostics. He also co-founded Apceth, a German biotech company, and he holds academic appointments at the Ludwig-Maximilians-University in Munich and the Wake Forest Institute for Regenerative Medicine.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.